Premature Ventricular Contractions During the Recovery Phase of Exercise Are Only Associated with Increased Cardiovascular Mortality when Present Together with Echocardiographic Abnormalities

Thomas Lindow, MD, PhD[1-3], Magnus Ekström, MD, PhD,[4] Lars Brudin, MD, PhD,[5] Kristofer Hedman, MD, PhD,[6] Martin Ugander, MD, PhD[1,7]

1. Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia
2. Department of Clinical Physiology, Research and Development, Växjö Central Hospital, Region Kronoberg, Sweden
3. Clinical Physiology, Faculty of Medicine, Clinical Sciences, Lund University, Sweden
4. Lund University, Faculty of Medicine, Clinical Sciences, Respiratory Medicine and Allergology, Lund, Sweden
5. Department of Clinical Physiology, Kalmar County Hospital, Kalmar Sweden
6. Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
7. Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

Funding: TL is under the support of postdoctoral research grants from The Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian Society of Clinical Physiology & Nuclear Medicine.

ME is funded by an unrestricted grant from the Swedish Research Council (Dnr: 2019-02081).

KH is funded by unrestricted ALF grants from county council of Östergötland.

MU is funded by New South Wales Health, Heart Research Australia, and the University of Sydney.

Competing interests:

The authors declare no competing interests.

Corresponding author: Thomas Lindow, +61 406 754, Thomas.a.lindow@gmail.com,

Clinical Physiology, Clinical Sciences, Lund University

Background: Premature ventricular contractions (PVCs) during the recovery of exercise stress testing are associated with increased cardiovascular mortality, but the cause remains unknown. We aimed to evaluate the association of PVCs during recovery with abnormalities on echocardiography, and to evaluate their combined prognostic performance.

Methods: Echocardiographic abnormalities (reduced left ventricular (LV) ejection fraction, valvular heart disease, LV dilatation, LV hypertrophy, or increased filling pressures) and the presence of PVCs during recovery ($\geq$1/min) were identified among patients having undergone resting echocardiography within median [interquartile range] 0 [0-2] days of an exercise stress test. The association between such changes and cardiovascular mortality was analyzed using Cox regression adjusted for age, sex, clinical and exercise variables.

Results: Among included patients (n=3,106, 219 events, 7.9 [5.4–11.1] years follow-up), PVCs during recovery was found in 1,327 (43%) patients, among which prevalence of echocardiographic abnormalities was increased (58% vs. 43%, p<0.001). Overall, PVCs during recovery was associated with increased cardiovascular mortality (adjusted hazard ratio (HR) [95% confidence interval] 1.6 [1.2–2.1], p<0.001). When combined with echocardiographic abnormalities, PVCs during recovery was only associated with increased risk when such were present (adjusted HR 3.3 [2.0–5.4], p<0.001), and not when absent (adjusted HR 1.4 [0.7–2.6], p=0.26), in reference to those with neither.

Conclusion: PVCs during recovery was associated with increased prevalence of echocardiographic abnormalities. Increased risk of cardiovascular mortality was observed only for subjects with PVCs if concomitant echocardiographic abnormalities were present. This provides a structural explanation for the increased long-term cardiovascular risk among patients with PVCs during recovery.

Abbreviations

PVC: premature ventricular contractions

HR: hazard ratio

LVEF: left ventricular ejection fraction

AV: aortic valve

LA: left atrium/atrial

LV: left ventricle/ventricular

Introduction

Exercise-induced premature ventricular contractions (PVCs) are common findings in exercise stress testing and have been described to associate with increased risk of cardiovascular mortality, especially when occurring during the recovery phase [1-11]. This has been observed in patients across a wide range of clinical risk profiles, from presumably healthy, asymptomatic individuals to patients with established cardiovascular disease [1-4, 6, 7, 11-13]. This suggests that the etiology of PVCs during recovery is multifactorial although the cause remains to be elucidated. PVCs during recovery after exercise have been suggested to be caused by imbalances in autonomic tone [5, 6, 14], or to be related to myocardial ischemia [12]. Despite the extensive data on prognostic information from exercise-induced PVCs, data on structural heart disease in patients with PVCs during the recovery phase are scarce, and restricted to assessment of left ventricular ejection fraction (LVEF) [1, 15]. Therefore, we aimed to investigate the association of PVCs during recovery after bicycle exercise stress with abnormalities on echocardiographic examination, and to evaluate the prognostic value of the combination of PVCs during recovery and abnormal findings on echocardiography.

Methods

We performed a consecutive cohort study including patients aged 18 years or older who had performed a clinical bicycle exercise stress test and a resting transthoracic echocardiography within 90 days of the exercise stress test at the Department of Clinical Physiology at Kalmar County Hospital, Sweden, between 31 May 2005 and 31 Oct 2016. The exercise stress test database has been described in detail elsewhere [16-19]. We excluded those who had an exercise time less than 3 minutes or had atrial fibrillation, considering the challenge of distinguishing aberrantly conducted supraventricular complexes from PVCs. Inclusion and

exclusion criteria are shown in Fig. 1. The database has been cross-linked with comorbidity

and hospital admission data in the Swedish National Patient Register, and with the Swedish

National Causes of Death Register to obtain survival status of all patients (up to 31 Dec

2019)[20]. List of definitions of comorbid conditions including International Classification of

Diseases (ICD) codes can be found in Supplemental Table A.

Exercise stress testing

Exercise stress testing was performed according to a nationally standardized protocol on an

electronically braked, regularly calibrated bicycle ergometer (Rodby Inc, Karlskoga, Sweden)

and commenced at a starting load of 40–100 W for males and 30–50W for females, with an

incremental increase of 10–20 W/min [21]. A 12-lead ECG was recorded at rest, during

exercise and the recovery phase which lasted at least 4 minutes (CASE 12; Marquette

Electronics Inc., Milwaukee, WI, USA and CASE v 6.51, GE Healthcare, Milwaukee, WI,

USA). Every 2 minutes during exercise, the patients were queried regarding rating of

perceived exercise (RPE), and systolic blood pressure was measured. The test was terminated

at the patient's will or if any termination criteria were fulfilled (severe chest pain, ST-

depression ≥0.4 mV, a drop in systolic blood pressure or occurrence of severe arrhythmia

(ventricular tachycardia (VT) defined as at least 3 PVCs in a row, PVCs in increasing

frequency or complexity, supraventricular tachycardia >200/min, or AV block II or III

occurring during exercise) [21]. At termination of exercise, the patient was directly returned

to supine position.

ECG abnormalities at rest before, after, and during stress were noted by the attending

physician at the time of the test and were not re-interpreted for the purpose of this study. Peak

workload was related to nationally standardized reference values (% of predicted W_{max}) [19].

The amplitude and slope of the ST segment during the exercise stress test were measured 60

ms following the J-point (ST60). For this study, ST depression was defined as horizontal or

down-sloping ST depression ≥0.1 mV in V5 during exercise or during the recovery phase.

Heart rate recovery was defined as the difference in heart rate between the maximal heart rate

and the heart rate 1 min after cessation of exercise [22, 23]. For patients who had performed

more than one test, only the most recent test was included.

Frequency of PVCs in the recovery phase

PVC frequency during recovery was graded and noted at the time of the stress test according

to clinical routine as either <1 PVC/min, 1–5 PVCs/min, 5–10/min, or >10/min during the

first 4 minutes of recovery. Studies have applied different definitions of frequent PVCs [1-7,

9, 10], ranging from the use of the median frequency in the dataset (frequent = above the

median) [1, 6, 10], to 10% of all depolarizations within a specific time frame [4, 7, 9], or a

fixed value, e.g. >10/min [3]. Any cutoff would be arbitrary and previous studies have shown

that cardiovascular risk may be similar for patients with frequent PVCs compared to those

with infrequent PVCs [6]. This suggests that the prognostic significance lies in the presence of

PVCs during recovery rather than the quantity. Consequently, we chose to primarily divide

our study population into two groups based on <1 or ≥1 PVC/min during the first 4 minutes of

recovery. Since most previous study used a fixed value definition (>10/min) we included this

as a supplemental analysis.

Echocardiography

Standard echocardiographic examinations were acquired during clinical routine by skilled

ultrasound technicians under physician supervision. Left ventricular (LV) and atrial (LA)

diameters were obtained either from M-mode or 2D measures. LV ejection fraction (EF) was

reported either based on the Simpson biplane method, from M-mode data, or by visual

estimation. Data on grade of aortic, mitral or tricuspid regurgitation (0 – 3: none, mild,

moderate, severe) were extracted from the echocardiographic reports. Moderate aortic

stenosis was defined as aortic valve (AV) maximal velocity by continuous wave Doppler

≥3.1–4.0 m/s or AV mean gradient 20–40 mm Hg, and severe aortic stenosis as AV maximal

velocity ≥4.0 m/s or AV mean gradient ≥40 mm Hg [24].

Left-sided cardiac dimensions (LV diameter, LA diameter, LV mass, LVEF) were considered

abnormal if they exceeded established sex-based reference values [25]. LV mass was

calculated according to the Cube formula (LV mass (g) = 0.8 x 1.04 ([IVS + LVID + PW]^3 –

LVID^3) + 0.6) [25]. Significant valvular heart disease was defined as at least moderate

aortic/mitral/tricuspid regurgitation or at least moderate aortic stenosis. Increased right

ventricle to right atrial (RV–RA) pressure gradient was defined as a tricuspid regurgitant

velocity exceeding 2.8 m/s. Increased LV filling pressures were defined as E/e' ≥15 and a

moderately enlarged LA, or E/e' ≥15 and an increased RV–RA pressure gradient. An

echocardiographic abnormality was considered present if any of the following criteria were

met: a) reduced LVEF, b) significant valvular heart disease, c) LV dilatation, d) increased LV

filling pressures or e) LV hypertrophy

Ethical considerations

The study complies with the Declaration of Helsinki and was approved by the Regional

Ethical Review Board (Dnr 2012/379-31; 2018/141-31 and 2020/00352). Informed consent

was waived by the Ethical Review Board.

Statistical analysis

Continuous variables were described using mean±standard deviation [SD], or as median [interquartile range]. Proportional differences between groups were assessed using the χ2 test. Comparison of group means was performed using Student's t test or analysis of variance (ANOVA). In order to be able to account for baseline differences in age and sex, the relation between the frequency of PVCs in the stress test recovery phase and subsequent findings on echocardiography was described not only as proportions, but also using odds ratios (OR) with 95% confidence intervals (CI) from multivariable logistic regression.

Time-to-event analysis was performed using Kaplan-Meier analysis with censoring at study end (31 Dec 2019). The association between PVCs during recovery and cardiovascular mortality was analyzed using multivariable Cox proportional hazard regression models; unadjusted and adjusted for age, sex, hypertension, heart failure, ischemic heart disease, diabetes mellitus, body mass index, peak workload, maximal heart rate, maximal systolic blood pressure, heart rate recovery, ST depression, and echocardiographic abnormalities. Further, the combination of PVCs during recovery and presence/absence of echocardiographic abnormalities were analyzed unadjusted and adjusted for age, sex, hypertension, heart failure, ischemic heart disease, diabetes mellitus, body mass index, peak workload, maximal heart rate, maximal systolic blood pressure, heart rate recovery, ST depression. Hazard ratios (HR) with 95% CI were presented. The assumption of proportional hazards was confirmed using Schoenfeld's residuals.

The proportions of different echocardiographic abnormalities were described for patients with PVCs who died during follow-up in comparison with patients with PVCs during recovery who did not.

The likelihood of frequent PVCs during recovery was assessed by univariate and

multivariable logistic regression analysis. Age, male sex, relevant comorbidities (diabetes,

hypertension, ischemic heart disease), echocardiographic variables (at least moderate valvular

heart disease, LVEF, E/e', left atrial diameter, left ventricular diameter) and exercise variables

assumed to be related to parasympathetic tone (resting heart rate, difference in heart rate from

supine rest to sitting, heart rate recovery, % of predicted maximal heart rate) were included in

univariate analysis and subsequently in the multivariable analysis if the p value was less than

0.1.

The following sensitivity analyses were performed in relation to the Cox regression analysis:

1) excluding patients with PVCs at rest according to the clinical resting ECG report, since

frequent PVCs during the recovery phase could reflect frequent PVCs at rest although

unrelated to exercise, and 2) including only patients who underwent echocardiography more

than 3 months after the exercise stress test, since there may be a selection bias when only

those that were referred for both exercise stress test and echocardiography at almost the same

time were included, and 3) stratifying patients based on the frequency of PVCs during the

recovery phase according to either <1 PVC/min, 1–5/min, ≥5–10, >10/min. The results of the

sensitivity analyses are presented as supplemental material.

Statistical significance was accepted at the level of $p<0.05$ (two-sided). Statistical analysis

was performed using R v. 3.5.3 (R Core Team (2021). R: A language and environment for

statistical computing. R Foundation for Statistical Computing, Vienna, Austria

(https://www.R-project.org/).

Results

In total, 3,106 patients were included (age 59 ± 16 years, 54.5% males) and followed prospectively for a median 7.9 years [IQR 5.4–11.1, range 0 – 15] years, range 0.0–14.6 years.

PVCs during the recovery phase were present in 1,327 (42.7%) patients. During follow-up, 219 (7.1%) patients died from a cardiovascular cause (10.4% of patients with vs. 4.6% without PVCs during recovery phase, p<0.001). Baseline characteristics based on the presence of PVCs during the recovery phase are presented in Table 1. Besides older age and a larger proportion of male subjects among those with than without PVCs during recovery, there were no major differences in comorbidities between groups. Peak workload was lower in patients with PVCs during recovery, but the difference in peak workload as % of predicted was not clinically relevant. A larger proportion of tests were terminated by the physician due to arrhythmia among those with PVCs during recovery (Table 1).

An echocardiographic examination was performed within 1 day of the exercise stress test in 74.6% of patients, median [interquartile range] 0 [0-2] days. An increased prevalence of echocardiographic abnormalities was found for patients with PVCs during the recovery phase (57.6% vs 42.9%, p<0.001 (Table 2). Mean LVEF was only slightly lower in patients with frequent PVCs during the recovery phase (62% vs 64%, p<0.001), but the proportion of patients with reduced LVEF was higher in patients with PVCs during recovery compared to those without (14% vs. 9%, p<0.001). PVCs during recovery was associated with increased odds of having echocardiographic abnormalities, even after adjustment for age and sex differences in all patients (OR 1.4 [1.2–1.6], p<0.001). The association was similar both among patients without previously known cardiovascular disease (OR 1.4 [1.1–1.7], p=0.001), and among patients with known cardiovascular disease (OR 1.4 [1.1–1.8], p=0.008). PVCs during recovery was associated with increased cardiovascular mortality

237 (unadjusted HR 2.6 [2.0–3.4], and HR adjusted for age, sex, clinical variables, and exercise

238 stress testing variables and echocardiographic abnormalities 1.6 [1.2–2.1] (Supplemental

239 Table B). However, in combination with either presence or absence of echocardiographic

240 abnormalities, PVCs during recovery were only associated with increased risk of

241 cardiovascular death when echocardiographic abnormalities were present. The risk for

242 patients with PVCs during recovery but no echocardiographic abnormalities was not increased

243 relative to those with <1 PVCs/min during recovery and the absence of echocardiographic

244 abnormalities (Table 3, Fig. 2 and 3). The proportion of echocardiographic abnormalities in

245 patients with PVCs during recovery stratified by cardiovascular death during follow-up is

246 presented in Figure 4.

247 In multivariable analysis, age, male sex, LV diameter, LV mass, and maximal % of predicted

248 heart rate were the only independent predictors of PVCs during the recovery phase. Beyond

249 maximal % of predicted heart rate, indicators of abnormal autonomic tone, such as heart rate

250 recovery, were not associated with increased frequency of PVCs during the recovery phase in

251 multivariable analysis (Supplements Table B).

253 **Discussion**

254 The two main findings of the current study were that exercise-induced PVCs during the

255 recovery phase associated with an increased cardiovascular mortality, and that this was only

256 apparent when present together with echocardiographic abnormalities. These findings have

257 two important implications. Firstly, these results propose a structural explanation as to why

258 frequent exercise-induced PVCs are associated with increased long-term cardiovascular risk,

259 which previously has been largely unknown. Secondly, the occurrence of PVCs during

recovery implies that the diagnostic yield of subsequent echocardiography can be expected to

be higher, therefore warranting further evaluation in search of structural heart disease.

We found that patients with PVCs during the recovery phase had slightly lower mean LVEF

as well as a higher proportion with reduced LVEF, compared to those without PVCs. Previous

reports from cardiac imaging in the setting of exercise-induced PVCs have been restricted to

the assessment of LVEF [1]. Frolkis, *et al,* studied the prognostic value of PVCs during the

recovery phase in almost 30,000 patients without a history of heart failure, valvular heart

disease, or arrhythmia, and found it to be a stronger predictor of all-cause death than PVCs

during exercise. In 6,421 of these patients, LVEF was assessed either by echocardiography or

by contrast ventriculography within 3 months following the stress test. That study had similar

findings as the current study, albeit with a higher prevalence of reduced LVEF among patients

with frequent PVCs during recovery compared to those without (28% *vs.* 13%).

This study adds to the current literature by showing that PVCs during recovery are associated

with a high rate of structural heart disease including LV hypertrophy, LV dilatation, increased

LV filling pressures, and valvular heart disease (regurgitant lesions in particular). Moreover,

several of these findings were increasingly common in those with PVCs during recovery who

died during follow-up, compared to those who survived. These findings suggest the need for

future research using more comprehensive cardiac imaging in patients with increased PVC

during recovery, such as cardiovascular magnetic resonance imaging.

Another novel finding was that patients with PVCs during recovery but no echocardiographic

abnormalities did not have a higher cardiovascular mortality compared to those with neither

of these two findings. By comparison, those with both echocardiographic abnormalities and

PVCs during recovery had the worst outcomes, suggesting that there is an important

association between structural heart disease and PVCs detected during the recovery phase of

an exercise stress test. The increased risk of PVCs during recovery in subjects with structural

heart disease agrees well with findings of increased risk among patients with frequent PVCs

at rest in combination with structural heart disease [26, 27]. Our results identify potential

mechanisms that may underpin and mediate the worsened prognosis in patients with PVCs

during the recovery phase [1-6]. This is the first study to include detailed information based

on cardiac imaging in this evaluation. Furthermore, we found no association between exercise

variables that are reasonable to assume to be related to autonomic tone and the occurrence of

PVCs during the recovery phase, after adjusting for age, sex and echocardiographic findings.

Increased cardiovascular mortality has been observed both in low- and high-risk patients, and

autonomic abnormalities have been suggested as a plausible cause [5, 6, 14]. However, the

results of the current study provide evidence that does not support such an association, but

instead suggests that structural heart disease is present in the majority of these cases.

Limitations

The findings of the current study are based on data from patients who performed both an

exercise stress test and an echocardiogram based on clinical referral. This may induce

selection bias, and groups of patients that are not referred for echocardiograms may have a

different proportion of abnormal findings. Therefore, we performed a sensitivity analysis for

those who performed an echocardiogram >90 days after the exercise test with highly similar

results regarding the prognostic value (Supplements, Table D), which strengthens the

generalizability of our results and suggesting that the problem of selection bias in this case is

of minor importance.

This is a registry-based study limited by not having access to raw ECG or imaging data but

rather relying on the clinical reports with tabulated values. Further, the classifications used

relied on the number of PVCs only, i.e. not taking into account the complexity of ventricular

arrythmia such as couplets, bigeminy or VT. The number of tests prematurely terminated due

to severe arrhythmia among those with no or low-grade PVCs was small, indicating that this

likely did not have had a substantial impact on the findings. Another limitation associated

with not having access to the ECG recording is that the anatomical origin of PVCs could not

be analyzed. Furthermore, measurements of RV and RA dimensions were not available and

rare diagnoses such as arrhythmogenic right ventricular cardiomyopathy were therefore not

evaluated. Nonetheless, they are expected to constitute a very small number of patients [28].

Conclusion

PVCs during the recovery phase of exercise stress testing was associated with increased risk

of abnormal findings on echocardiography and provided incremental prognostic information.

However, increased cardiovascular mortality was observed only for those subjects with

frequent PVCs who had concomitant echocardiographic abnormalities. Our findings provide a

possible explanation for the increased long-term cardiovascular risk reported in patients with

PVCs during recovery and can help clinicians to guide which patients who would benefit

from further echocardiographic follow-up after exercise testing.

Table 1. Baseline characteristics including exercise stress test characteristics stratified by frequency of premature ventricular contractions during the recovery phase

	PVC frequency during recovery phase	
	<1/min	≥1/min
Number of patients	1,779	1,327
Age, years	55.6±17.0	65.6±13.3
Male sex, n (%)	901 (50.6)	792 (59.7)
Hypertension, n (%)	265 (14.9)	216 (16.3)
Diabetes, n (%)	149 (8.4)	133 (10.0)
Ischemic heart disease, n (%)	164 (9.2)	133 (10.0)
of which, myocardial infarction, n (%)	82 (4.6)	46 (3.5)
Cerebrovascular disease, n (%)	32 (1.8)	36 (2.7)
COPD, n (%)	22 (1.2)	40 (3.0)
Clinical HF classification		
No HF, n (%)	1,651 (92.8)	1,168 (88.0)
HFpEF, n (%)	33 (1.9)	39 (2.9)
HFmrEF, n (%)	43 (2.4)	63 (4.7)
HFrEF, n (%)	52 (2.9)	57 (4.3)
Medications		
ACE inhibitor, n (%)	288 (16.2)	289 (21.8)

Betablocker, n (%)		486 (27.3)	419 (31.6)
Loop diuretics, n (%)		136 (7.6)	126 (9.5)
Calcium antagonists, n (%)		219 (12.3)	194 (14.6)
Thiazide diuretics, n (%)		92 (5.2)	90 (6.8)
Anti-thrombotic, n (%)		355 (20.0)	372 (28.0)
Nitrates, n (%)		203 (11.4)	197 (14.8)
Anti-arrhythmic, n (%)		4 (0.2)	1 (0.1)
Anti-coagulant, n (%)		46 (2.6)	62 (4.7)
Exercise stress test variables			
Peak workload, W		156±62	144±53
Peak workload, % of predicted		86±19	84±18
PVCs during exercise, n (%)			
	1 – 5/min	346 (19.4)	654 (49.3)
	5 – 10/min	17 (1.0)	159 (12.0)
	>10/min	2 (0.1)	18 (1.4)
Test terminated due to arrhythmia, n (%)		3 (0.2)	35 (2.6)
Resting heart rate, beats/min		73±14	72±13
Maximum heart rate, beats/min		148±26	143±25
Heart rate recovery, beats/min		31±15	28±15
Maximum SBP, mm Hg		189±30	192±30
RPE (6 – 20), units		17.2±1.1	16.9±1.2
ST depression, n (%)		151 (8.5)	212 (16.0)

Data presented as mean±standard deviation or n (%).

Abbreviations: ACE: angiotensin converting enzyme; COPD: chronic obstructive pulmonary disease; HF: heart failure; HFmrEF: heart failure with moderately reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; PVC: premature ventricular contractions; SBP, systolic blood pressure; W: watts

Table 2. Echocardiographic outcomes stratified by occurance of premature ventricular contractions during the recovery phase.

	PVC frequency during recovery phase		
	<1/min	≥1/min	
Number of patients	1,779	1,327	p
LV diameter, mm	47±5	49±6	<0.001
LA diameter, mm	38±6	40±6	<0.001
LVEF, %	64±11	62±11	0.001
Wall thickness, septum, mm	10.7±2.2	11.3±2.2	<0.001
Wall thickness, posterior wall, mm	10.1±1.9	10.6±1.8	<0.001
E/A ratio, unitless	1.2±0.5	1.1±0.4	<0.001
E/e', unitless	10.3±4.3	11.2±4.4	<0.001
AV V_{max}, m/s	1.5±0.5	1.6±0.7	<0.001
VTI_{LVOT}, cm	21.4±4.1	20.9±4.2	0.001
Moderate/severe AS, n (%)	49 (2.8)	144 (10.9)	0.042
Moderate/severe AR, n (%)	43 (2.4)	49 (3.7)	0.049
Moderate/severe MR, n (%)	96 (5.4)	135 (10.2)	<0.001
Moderate/severe TR, n (%)	121 (6.8)	144 (10.9)	<0.001
TR velocity, m/s	2.3±0.3	2.4±0.3	<0.001
Increased RV-RA gradient, n (%)	62 (3.5)	80 (6.5)	0.001
Reduced LVEF, n (%)	163 (9.2)	191 (14.4)	<0.001

LV dilatation, n (%)	80 (4.5)	102 (7.7)	<0.001
Increased LV mass, n (%)	439 (24.7)	453 (34.1)	<0.001
Significant valve disease, n (%)	244 (13.7)	289 (21.8)	<0.001
Increased filling pressures, n (%)	63 (3.5)	87 (6.6)	<0.001
Echocardiographic abnormality, n (%)	763 (42.9)	764 (57.6)	<0.001

Data presented as mean±standard deviation or n (%).

Abbreviations: AR: aortic regurgitation; AS: aortic stenosis; LA: left atrial; LV: left ventricular; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; PVC: premature ventricular contractions; TR: tricuspid regurgitation.

Table 3. Hazard ratios [95%CI] for cardiovascular mortality based on combination of absence/presence of PVCs during recovery, and presence or absence of significant echocardiographic abnormalities, n=3,106 (219 events)

	Unadjusted	Adjusted for age, sex, clinical[†] and exercise variables§
PVC-/ECHO-	1.0	1.0
PVC+/ECHO-	2.4 [1.3–4.4]	1.4 [0.7 –2.6]
PVC-/ECHO+	4.0 [2.4–6.7]	2.0 [1.2–3.3]
PVC+/ECHO+	8.5 [5.2–13.8]	3.3 [2.0–5.4]

Abbreviations: ECHO-: no significant abnormality on echocardiography; ECHO+: significant abnormality on echocardiography; PVC: premature ventricular contractions; PVC-: <1 PVCs/min during recovery; PVC+:≥1 PVCs/min during recovery.

[†] Hypertension, diabetes, ischemic heart disease, heart failure, body-mass index

§ Peak workload, maximal heart rate, heart rate recovery, maximal systolic blood pressure, ST depression

Figure legends

Figure 1. Flow chart of patient inclusion and exclusion.

Figure 2. Time-to-event analysis for the combination of frequent PVCs during recovery and

abnormalities on echocardiography among 3,106 patients experiencing 219 cardiovascular

mortality events during 7.9 [5.4–11.1] years of follow-up. PVC-: <1 PVCs/min during

recovery; PVC+: ≥1 PVCs/min during recovery; ECHO-: absence of abnormality on

echocardiography; ECHO+: abnormality on echocardiography. An echocardiographic

abnormality was defined as either: reduced left ventricular ejection fraction, at least moderate

valvular heart disease, left ventricular dilatation, increased left ventricular mass, or increased

left ventricular filling pressures.

Figure 3. Forest plot showing hazard ratios for cardiovascular death with 95% confidence

limits (adjusted for age, sex, hypertension, heart failure, ischemic heart disease, diabetes

mellitus, body mass index, peak workload, maximal heart rate, maximal systolic blood

pressure, heart rate recovery and ST depression) based on combinations of presence/absence

of PVC during recovery and echocardiographic abnormalities. PVC-: <1 PVCs/min during

recovery; PVC+: ≥1 PVCs/min during recovery; ECHO-: absence of abnormality on

echocardiography; ECHO+: abnormality on echocardiography. An echocardiographic

abnormality was defined as either: reduced left ventricular ejection fraction, at least moderate

valvular heart disease, left ventricular dilatation, increased left ventricular mass or increased

filling pressures defined as E/e' ≥15 and either moderately enlarged LA or increased RV–RA

pressure gradient.

Figure 4. Prevalence of echocardiographic abnormalities in patients with PVC during

recovery (n=1,327) stratified by cardiovascular (CV) death during follow-up (CV death:

n=138 (red bars); no death: 1,189 (light blue bars). *** = <0.001, * = <0.05

Abbreviations: LV: left ventricular; LVEF: left ventricular ejection fraction; LA: left atrial;

RV: right ventricle; RA: right atrium. Echocardiographic abnormalities were more common in

patients with PVC during recovery and an adverse outcome.

References

1.   Frolkis JP, Pothier CE, Blackstone EH, et al. Frequent ventricular ectopy after

exercise as a predictor of death. N Engl J Med. 2003;348:781-90.

2.   O'Neill JO, Young JB, Pothier CE, et al. Severe frequent ventricular ectopy after

exercise as a predictor of death in patients with heart failure. J Am Coll Cardiol. 2004;44:820-

6.

3.   Refaat MM, Gharios C, Moorthy MV, et al. Exercise-Induced Ventricular

Ectopy and Cardiovascular Mortality in Asymptomatic Individuals. J Am Coll Cardiol.

2021;78:2267-77.

4.   Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men

with exercise-induced premature ventricular depolarizations. N Engl J Med. 2000;343:826-33.

5.   Lee V, Perera D,Lambiase P. Prognostic significance of exercise-induced

premature ventricular complexes: a systematic review and meta-analysis of observational

studies. Heart Asia. 2017;9:14-24.

6.   Dewey FE, Kapoor JR, Williams RS, et al. Ventricular arrhythmias during

clinical treadmill testing and prognosis. Arch Intern Med. 2008;168:225-34.

7.   Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict

cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid

research clinics prevalence study. JAMA. 2003;290:1600-7.

8.   Beckerman J, Mathur A, Stahr S, et al. Exercise-induced ventricular arrhythmias

and cardiovascular death. Ann Noninvasive Electrocardiol. 2005;10:47-52.

9.   Partington S, Myers J, Cho S, et al. Prevalence and prognostic value of exercise-

induced ventricular arrhythmias. Am Heart J. 2003;145:139-46.

10.   Morshedi-Meibodi A, Evans JC, Levy D, et al. Clinical correlates and

prognostic significance of exercise-induced ventricular premature beats in the community: the

Framingham Heart Study. Circulation. 2004;109:2417-22.

11.   Henry RL, Kennedy GT,Crawford MH. Prognostic value of exercise-induced

ventricular ectopic activity for mortality after acute myocardial infarction. Am J Cardiol.

1987;59:1251-5.

12.   Dzikowicz DJ,Carey MG. Exercise-Induced Premature Ventricular Contractions

Are Associated With Myocardial Ischemia Among Asymptomatic Adult Male Firefighters:

Implications for Enhanced Risk Stratification. Biol Res Nurs. 2020;22:369-77.

13.   Kim J, Kwon M, Chang J, et al. Meta-Analysis of Prognostic Implications of

Exercise-Induced Ventricular Premature Complexes in the General Population. Am J Cardiol.

2016;118:725-32.

14.   Frigy A, Csiki E, Caraşca C, et al. Autonomic influences related to frequent

ventricular premature beats in patients without structural heart disease. Medicine (Baltimore).

2018;97:e11489.

15.   Saha SA. Premature Ventricular Complexes During Exercise in Asymptomatic

Adults: Do They Deserve a Closer Look? J Am Coll Cardiol. 2021;78:2278-80.

16.   Lindow T, Brudin L, Elmberg V, et al. Long-term follow-up of patients

undergoing standardized bicycle exercise stress testing: new recommendations for grading of

exercise capacity are clinically relevant. Clin Physiol Funct Imaging. 2019.

17.   Lindow T, Ekström M, Brudin L, et al. Typical angina during exercise stress

testing improves the prediction of future acute coronary syndrome. Clin Physiol Funct

Imaging. 2021;41:281-91.

18.   Hedman K, Lindow T, Elmberg V, et al. Age- and gender-specific upper limits

and reference equations for workload-indexed systolic blood pressure response during bicycle

ergometry. Eur J Prev Cardiol. 2020;2047487320909667.

19.   Brudin L, Jorfeldt L,Pahlm O. Comparison of two commonly used reference

materials for exercise bicycle tests with a Swedish clinical database of patients with normal

outcome. Clin Physiol Funct Imaging. 2014;34:297-307.

20.   Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register.

Eur J Epidemiol. 2017;32:765-73.

21.   Jorfeldt L,Pahlm O. Kliniska arbetsprov : metoder för diagnos och prognos:

Studentlitteratur; 2013.

22.   Sipila K, Tikkakoski A, Alanko S, et al. Combination of low blood pressure

response, low exercise capacity and slow heart rate recovery during an exercise test

significantly increases mortality risk. Ann Med. 2019;51:390-6.

23.   Cole CR, Blackstone EH, Pashkow FJ, et al. Heart-rate recovery immediately

after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351-7.

24.   Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the

management of valvular heart disease. Eur Heart J. 2017;38:2739-91.

25.   Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber

quantification by echocardiography in adults: an update from the American Society of

Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J

Cardiovasc Imaging. 2015;16:233-70.

26.   Dukes JW, Dewland TA, Vittinghoff E, et al. Ventricular Ectopy as a Predictor

of Heart Failure and Death. J Am Coll Cardiol. 2015;66:101-9.

27.   Sassone B, Muser D, Casella M, et al. Detection of concealed structural heart

disease by imaging in patients with apparently idiopathic premature ventricular complexes: A

review of current literature. Clin Cardiol. 2019;42:1162-9.

28.   Corrado D, Basso C,Judge DP. Arrhythmogenic Cardiomyopathy. Circulation

research. 2017;121:784-802.

SUPPLEMENTS

Supplemental Table A. Definitions of diagnoses included for the purposes of demographic
characteristics.

Diagnosis	Definition
Hypertension	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Hypertensive diseases (I10x-I15x)
Hyperlipidemia	Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Disorders of lipoprotein metabolism and other lipidemias (E78x)
Diabetes mellitus	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Type I (E10x), Type II (E12X), Other (E13x-E14x)
Heart failure	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Heart failure (I50x) 2. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Cardiomyopathy (I42x-I43x) 3. Left ventricular ejection fraction <50% at the echocardiographic examination 4. Incident heart failure diagnosis within 3 months of the echocardiographic study (I50x)
Chronic obstructive pulmonary disease	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Bronchitis (J40x-J42x); Emphysema (J43); Other COPD (J44x)
Atrial fibrillation/flutter	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Atrial fibrillation and flutter (I48x)
Ischemic heart disease	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Angina pectoris (I20.9). 2. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Acute myocardial infarction (I21x); Subsequent myocardial infarction (I22x); Complication following acute myocardial infarction (I23x); Other acute ischemic heart disease (I24x) 3. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Unstable angina (I20.0)
Acute myocardial infarction	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) Acute myocardial infarction (I21x); Subsequent myocardial infarction (I22x); Complication following acute myocardial infarction (I23x); Other acute ischemic heart disease (I24x)
Cerebrovascular disease	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) (ICD>="I60") & (ICD<="I69") Subarachnoid haemorrhage (I60x); Intracerebral haemorrhage (I61x); Other nontraumatic intracranial haemorrhage (I62x); Cerebral infarction (I63x); Stroke, not 3 specified (I64x); Occlusion and stenosis of arteries, not resulting in cerebral infarction (I65x-166x); Other cerebrovascular diseases (I67x); Cerebrovascular disorders in diseases classified elsewhere (I68x); Sequelae of cerebrovascular disease (I69x).
Cardiovascular disease	1. Prevalent diagnosis, hospital (outpatient, inpatient, admission; ICD10-codes) ICD Ix

Supplemental Table B. Hazard ratios with 95% confidence intervals from Cox regression analysis (univariate and multivariable) for cardiovascular death during follow-up

	Univariable analysis	Wald	p	Multivariable analysis	Wald	p
PVCs during recovery	2.59 [1.96–3.40]	6.8	<0.001	1.60 [1.20–2.13]	3.3	0.001
Echocardiographic abnormalities	4.16 [3.10–5.58]	9.5	<0.001	1.94 [1.41–2.65]	4.1	<0.001
Age, years	1.10 [1.09–1.12]	13.2	<0.001	1.04 [1.02–1.06]	4.2	<0.001
Male sex	1.59 [1.21–2.10]	3.3	0.001	4.56 [3.07–6.77]	7.5	<0.001
Peak workload, W	0.98 [0.98–0.98]	-10.9	<0.001	0.98 [0.97–0.99]	-6.6	<0.001
Peak SBP, mmHg	0.99 [0.99–1.00]	-2.8	0.005	1.00 [1.00–1.01]	1.0	0.3
Peak heart rate, min^{-1}	0.96 [0.95–0.96]	-14.4	<0.001	0.99 [0.98–1.00]	-2.2	0.03
Heart rate recovery, min^{-1}	0.92 [0.91–0.93]	-12.5	<0.001	0.98 [0.97–0.99]	-2.8	0.006
ST depression	2.14 [1.56–2.94]	4.7	<0.001	1.04 [0.75–1.46]	0.3	0.8
Heart failure	4.54 [3.39–6.07]	10.2	<0.001	1.64 [1.18–2.26]	3.0	0.003
Ischemic heart disease	2.76 [2.02–3.77]	6.4	<0.001	1.21 [0.86–1.70]	1.1	0.3
Hypertension	2.14 [1.57–2.92]	4.8	<0.001	1.19 [0.86–1.65]	1.0	0.3
Diabetes	2.31 [1.60–3.33]	4.5	<0.001	1.15 [0.78–1.69]	0.8	0.5
Body-mass index, kg/m^2	1.03 [1.00–1.05]	2.0	0.05	1.01 [0.98–1.00]	0.82	0.4

Abbreviations: PVC-: premature ventricular contractions; SBP: systolic blood pressure

Supplemental Table C. Univariate and multivariable analysis for the prediction of frequent PVCs during the recovery phase of exercise stress testing

Parameter	Univariate analysis		Multivariable analysis			
			Model 1		Final model	
	Odds ratio [95% CI]	p	Odds ratio [95% CI]	p	Odds ratio [95% CI]	p
Age, years	1.04 [1.04–1.05]	<0.001	1.04 [1.03–1.05]	<0.001	1.04 [1.04–1.05]	<0.001
Male sex	1.44 [1.25–1.67]	<0.001	1.18 [0.99–1.40]	0.06	1.24 [1.04–1.45]	<0.001
Valvular heart disease	1,75 [1.45–2.11]	<0.001	1.42 [0.98–1.47]	0.08	1.20 [0.98–1.47]	0.08
LV mass indexed to BSA, g/m^2	1.01 [1.01–1.02]	<0.001	1.00 [1.00–1.01]	0.05	1.00 [1.00–1.01]	0.04
LV diameter, mm	1.04 [1.03–1.06]	<0.001	1.05 [1.03–1.07]	<0.001	1.06 [1.04–1.08]	<0.001
LA diameter, mm	1.06 [1.05–1.07]	<0.001	1.01 [0.99–1.02]	0.23		
LVEF, %	0.98 [0.98–0.99]	<0.001	0.99 [0.98–1.00]	0.53		
% of pred. max heart rate	1.01 [100–1.02]	<0.001	1.02 1.02–1.03]		1.02 [1.01 – 1.03]	<0.001
E/e'	1.04 [1.03–1.06]	<0.001	0.98 [0.96–1.01]	0.13		
Heart rate recovery (min^{-1})	0.98 [0.98–0.99]	<0.001	1.00 [0.99–1.00]	0.17		
Resting heart rate (min^{-1})	0.99 [0.99–1.00]	0.75				
Heart rate increase to sitting (min^{-1})	1.00 [0.99–1.00]	0.24				
Ischemic heart disease	1.11 [0.87–1.40]	0.41				
Diabetes	1.22 [0.95–1.56]	0.11				

| Hypertension | 1.11 [0.91–1.35] | 0.29 | |

Abbreviations: BSA: body-surface area; CI: confidence interval; LVEF: left ventricular ejection fraction;

pred.: predicted.

Variables with a p<0.1 in the univariate analysis were included in the multivariable analysis, and subsequently

included in the final prediction model if p<0.1 at multivariable analysis.

Table D. Sensitivity analysis – echocardiography performed unrelated to the exercise stress test

Hazard ratios with 95% confidence intervals from Cox regression analysis, for the combination of PVCs during recovery and echocardiographic abnormalities in patients (n= 2,624, 228 events) who performed an echocardiographic study <u>more than 3 months after</u> the stress test (median 757 days, interquartile range 277 – 1,608 days).

	Unadjusted	Adjusted for age, sex, clinical[†] and exercise variables§
PVC-/ECHO-	1.0	1.0
PVC+/ECHO-	1.8 [0.9–3.3]	1.3 [0.7–2.4]
PVC-/ECHO+	3.5 [2.1–5.7]	1.8 [1.1–2.9]
PVC+/ECHO+	6.3 [3.09–10.7]	2.5 [1.5–.0]

Abbreviations: ECHO-: no significant abnormality on echocardiography; ECHO+: significant abnormality on echocardiography; PVC-: <1 PVCs/min during recovery; PVC+≥1 PVCs/min during recovery.

§Hypertension, diabetes, ischemic heart disease, heart failure, body-mass index, peak workload, maximal heart rate, heart rate recovery, ST depression

Table E. Sensitivity analysis – PVCs at rest

Hazard ratios with 95% confidence intervals from Cox regression analysis, for the combination of PVCs during recovery and echocardiographic abnormalities in patients without PVCs at resting ECG according to clinical report [n= 3,038, 215 events).

	Unadjusted	Adjusted for age, sex, clinical[†] and exercise variables§
PVC-/ECHO-	1.0	1.0
PVC/+/ECHO-	2.3 [1.3–4.3]	1.5 [0.8–2.7]
PVC-/ECHO+	4.0 [2.4–6.7]	2.0 [1.2–3.4]
PVC+/ECHO+	8.5 [5.3–13.8]	3.3 [2.0–5.3]

Abbreviations: ECHO-: no significant abnormality on echocardiography; ECHO+: significant abnormality on echocardiography; PVC-: <1 PVCs/min during recovery; PVC+≥1 PVCs/min during recovery

[†]Hypertension, diabetes, ischemic heart disease, heart failure, body-mass index

§Peak workload, maximal heart rate, heart rate recovery, ST depression

Table E. Sensitivity analysis – extended stratification based on PVC frequency
Hazard ratios with 95% confidence intervals from Cox regression analysis, for the combination of PVCs during recovery (<1, ≥1–5/min , ≥5–10/min or >10/min) and echocardiographic abnormalities (n= 3,106, 219 events).

	Unadjusted	Adjusted for age, sex, clinical☐ and exercise variables
PVC-/ECHO-	1.0	1.0
PVC-/ECHO+	4.2 [2.5–7.0]	2.0 [1.5–5.8]
PVC >1–5/min/ECHO-	2.4 [1.2–4.6]	1.5 [0.8–2.9]
PVC >1–5/min/ECHO+	8.2 [5.0–13.6]	3.5 [2.1–5.8]
PVC ≥5–10/min/ECHO-	4.5 [1.5–13.3]	2.4 [0.8–7.0]
PVC ≥5–10/min/ECHO+	10.7 [5.5–21.1]	2.9 [1.5–5.8]
PVC >10/min /ECHO-	1.9 [0.3–14.5]	0.9 [0.1–6.6]
PVC >10/min /ECHO+	13.5 [5.9–26.3]	2.9 [1.3–6.3]

Abbreviations: ECHO-: no significant abnormality on echocardiography; ECHO+: significant abnormality on echocardiography; PVC: premature ventricular contractions;

[†] Hypertension, diabetes, ischemic heart disease, heart failure, body-mass index

§ Peak workload, maximal heart rate, heart rate recovery, ST depression

498
499
500

13,857 patients who performed a clinical exercise stress test (bicycle ergometer) between 31 May 2005 and 31 Oct 2016

(age 57.3±17.3 years, 7,581 males, 6,276 females)

7,630 patients without echocardiogram performed
(age 57.0±14.3 years, 4,095 males, 3,535 females)

2,674 patients with an echocardiogram >3 months from the stress test
(age 64.7±12.4 years, 1,428 males, 1,246 females

362 patients with atrial fibrillation
(age 68.3±11.4years, 258 males, 104 females)

115 patients with exercise duration <3 min
(age 74.1±9.7 years, 57 males, 58 females)

3,106 adult patients with an echocardiogram performed within 3 months of a symtom-limited exercise stress test

(age 59.4±15.9 years, 1,693 males, 1,413 females)